Rationale for combined therapies in severe-to-critical COVID-19 patients
Aitor Gonzaga,Etelvina Andreu,Luis M Hernández-Blasco,Rut Meseguer,Karima Al-Akioui-Sanz,Bárbara Soria-Juan,Jose Carlos Sanjuan-Gimenez,Cristina Ferreras,Juan R Tejedo,Guillermo Lopez-Lluch,Rosa Goterris,Loreto Maciá,Jose M Sempere-Ortells,Abdelkrim Hmadcha,Alberto Borobia,Jose L Vicario,Ana Bonora,Cristobal Aguilar-Gallardo,Jose L Poveda,Cristina Arbona,Cristina Alenda,Fabian Tarín,Francisco M Marco,Esperanza Merino,Francisco Jaime,José Ferreres,Juan Carlos Figueira,Carlos Cañada-Illana,Sergio Querol,Manuel Guerreiro,Cristina Eguizabal,Alejandro Martín-Quirós,Ángel Robles-Marhuenda,Antonio Pérez-Martínez,Carlos Solano,Bernat Soria
DOI: https://doi.org/10.3389/fimmu.2023.1232472
2023-09-11
Abstract:An unprecedented global social and economic impact as well as a significant number of fatalities have been brought on by the coronavirus disease 2019 (COVID-19), produced by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Acute SARS-CoV-2 infection can, in certain situations, cause immunological abnormalities, leading to an anomalous innate and adaptive immune response. While most patients only experience mild symptoms and recover without the need for mechanical ventilation, a substantial percentage of those who are affected develop severe respiratory illness, which can be fatal. The absence of effective therapies when disease progresses to a very severe condition coupled with the incomplete understanding of COVID-19's pathogenesis triggers the need to develop innovative therapeutic approaches for patients at high risk of mortality. As a result, we investigate the potential contribution of promising combinatorial cell therapy to prevent death in critical patients.